Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis
Hidenori Toyoda(Ogaki Municipal Hospital), Yasuhito Tanaka(Nagoya City University), Takashi Kumada(Gifu Kyoritsu University), Toshifumi Tada(Ogaki Municipal Hospital), Toru Ishikawa(Saiseikai Niigata Daini Hospital), Etsuko Iio(Nagoya City University), Koichi Takaguchi(Kagawa Prefectural Central Hospital), Kunihiko Tsuji(Teine Keijinkai Hospital), Mikio Zeniya(International University of Health and Welfare)
Cited by 76
Related Papers
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|271
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers
|Hepatology|2012|195